Ivonescimab takes on pancreatic cancer
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
